Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10330504 | 0.80 | KMT2A (1.00) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL7856179 | 0.78 | KMT2A (0.73) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL15775276 | 0.77 | ESR1 (0.61) | KMT2AMEN1ALDH1A1TDP1ESR1 | |
| SCHEMBL28146177 | 0.77 | KMT2A (0.54) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL3455022 | 0.75 | HPGD (1.00) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL17339456 | 0.74 | KMT2A (0.51) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL3433281 | 0.74 | HPGD (0.50) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL20269157 | 0.74 | KMT2A (0.68) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL10517999 | 0.74 | HPGD (0.69) | KMT2AHPGDMEN1ALDH1A1TDP1 | |
| SCHEMBL31672210 | 0.74 | KMT2A (0.67) | KMT2AHPGDMEN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | disclosed |
| CN-1950375-A | Glucocorticoid receptor modulator compounds and methods- utility | LIGAND PHARM INC (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1718653-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | Ligand Pharmaceuticals Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082909-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | NR3C1, NR3C2, MC2R | KMT2A 4088/4885HPGD 272/4885MEN1 3261/4885 |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | NR3C1, NR3C2, MC2R | KMT2A 4088/4885HPGD 272/4885MEN1 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.